Cargando…
Lymphocyte reconstitution after allogeneic blood stem cell transplantation for hematologic malignancies
Forty-one patients were studied at set times after allogeneic blood stem cell transplantation (alloBSCT) for recovery of lymphocyte numbers and function. Cells were mobilized with G-CSF from HLA-matched related donors and cryopreserved. Graft-versus-host disease (GVHD) prophylaxis consisted of cyclo...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
1998
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7101861/ https://www.ncbi.nlm.nih.gov/pubmed/9486492 http://dx.doi.org/10.1038/sj.bmt.1701037 |
_version_ | 1783511709770579968 |
---|---|
author | Pavletic, ZS Joshi, SS Pirruccello, SJ Tarantolo, SR Kollath, J Reed, EC Bierman, PJ Vose, JM Warkentin, PI Gross, TG Nasrati, K Armitage, JO Kessinger, A Bishop, MR |
author_facet | Pavletic, ZS Joshi, SS Pirruccello, SJ Tarantolo, SR Kollath, J Reed, EC Bierman, PJ Vose, JM Warkentin, PI Gross, TG Nasrati, K Armitage, JO Kessinger, A Bishop, MR |
author_sort | Pavletic, ZS |
collection | PubMed |
description | Forty-one patients were studied at set times after allogeneic blood stem cell transplantation (alloBSCT) for recovery of lymphocyte numbers and function. Cells were mobilized with G-CSF from HLA-matched related donors and cryopreserved. Graft-versus-host disease (GVHD) prophylaxis consisted of cyclosporine and methotrexate; G-CSF was administered post-transplant. Median time to absolute lymphocyte count (ALC) ⩾500/μl was 17 days vs 41 and 49 days in historical alloBMT patients with G-CSF (n = 23) or no cytokine (n = 29) post-transplant, respectively (P < 0.0001). CD4/CD8(+) ratio was 1.9 on day 28 after alloBSCT, then gradually declined to 0.8 at 1 year due to more rapid CD8(+) cell recovery. Mean phytohemagglutinin-induced T cell responses were lower than normal on day +28 (P < 0.05), then tended to recover towards normal values. Natural-killer cytotoxicity remained low from day +28 to 1 year post-alloBSCT, but considerable lymphokine-activated killer cytotoxicity was induced from cells already obtained on day +28. Faster lymphocyte recovery correlated with better survival in alloBSCT patients (median follow-up 287 days, P = 0.002), ALC recovery was not affected by acute GVHD, CMV infections or doses of infused cells. ALC recovery did not correlate with survival in either historical alloBMT group. These data suggest that after alloBSCT lymphocyte reconstitution is faster than after alloBMT, and that quicker lymphocyte recovery predicts better survival in the alloBSCT setting. |
format | Online Article Text |
id | pubmed-7101861 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 1998 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-71018612020-03-31 Lymphocyte reconstitution after allogeneic blood stem cell transplantation for hematologic malignancies Pavletic, ZS Joshi, SS Pirruccello, SJ Tarantolo, SR Kollath, J Reed, EC Bierman, PJ Vose, JM Warkentin, PI Gross, TG Nasrati, K Armitage, JO Kessinger, A Bishop, MR Bone Marrow Transplant Article Forty-one patients were studied at set times after allogeneic blood stem cell transplantation (alloBSCT) for recovery of lymphocyte numbers and function. Cells were mobilized with G-CSF from HLA-matched related donors and cryopreserved. Graft-versus-host disease (GVHD) prophylaxis consisted of cyclosporine and methotrexate; G-CSF was administered post-transplant. Median time to absolute lymphocyte count (ALC) ⩾500/μl was 17 days vs 41 and 49 days in historical alloBMT patients with G-CSF (n = 23) or no cytokine (n = 29) post-transplant, respectively (P < 0.0001). CD4/CD8(+) ratio was 1.9 on day 28 after alloBSCT, then gradually declined to 0.8 at 1 year due to more rapid CD8(+) cell recovery. Mean phytohemagglutinin-induced T cell responses were lower than normal on day +28 (P < 0.05), then tended to recover towards normal values. Natural-killer cytotoxicity remained low from day +28 to 1 year post-alloBSCT, but considerable lymphokine-activated killer cytotoxicity was induced from cells already obtained on day +28. Faster lymphocyte recovery correlated with better survival in alloBSCT patients (median follow-up 287 days, P = 0.002), ALC recovery was not affected by acute GVHD, CMV infections or doses of infused cells. ALC recovery did not correlate with survival in either historical alloBMT group. These data suggest that after alloBSCT lymphocyte reconstitution is faster than after alloBMT, and that quicker lymphocyte recovery predicts better survival in the alloBSCT setting. Nature Publishing Group UK 1998-02-13 1998 /pmc/articles/PMC7101861/ /pubmed/9486492 http://dx.doi.org/10.1038/sj.bmt.1701037 Text en © Macmillan Publishers Limited 1998 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic. |
spellingShingle | Article Pavletic, ZS Joshi, SS Pirruccello, SJ Tarantolo, SR Kollath, J Reed, EC Bierman, PJ Vose, JM Warkentin, PI Gross, TG Nasrati, K Armitage, JO Kessinger, A Bishop, MR Lymphocyte reconstitution after allogeneic blood stem cell transplantation for hematologic malignancies |
title | Lymphocyte reconstitution after allogeneic blood stem cell transplantation for hematologic malignancies |
title_full | Lymphocyte reconstitution after allogeneic blood stem cell transplantation for hematologic malignancies |
title_fullStr | Lymphocyte reconstitution after allogeneic blood stem cell transplantation for hematologic malignancies |
title_full_unstemmed | Lymphocyte reconstitution after allogeneic blood stem cell transplantation for hematologic malignancies |
title_short | Lymphocyte reconstitution after allogeneic blood stem cell transplantation for hematologic malignancies |
title_sort | lymphocyte reconstitution after allogeneic blood stem cell transplantation for hematologic malignancies |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7101861/ https://www.ncbi.nlm.nih.gov/pubmed/9486492 http://dx.doi.org/10.1038/sj.bmt.1701037 |
work_keys_str_mv | AT pavleticzs lymphocytereconstitutionafterallogeneicbloodstemcelltransplantationforhematologicmalignancies AT joshiss lymphocytereconstitutionafterallogeneicbloodstemcelltransplantationforhematologicmalignancies AT pirruccellosj lymphocytereconstitutionafterallogeneicbloodstemcelltransplantationforhematologicmalignancies AT tarantolosr lymphocytereconstitutionafterallogeneicbloodstemcelltransplantationforhematologicmalignancies AT kollathj lymphocytereconstitutionafterallogeneicbloodstemcelltransplantationforhematologicmalignancies AT reedec lymphocytereconstitutionafterallogeneicbloodstemcelltransplantationforhematologicmalignancies AT biermanpj lymphocytereconstitutionafterallogeneicbloodstemcelltransplantationforhematologicmalignancies AT vosejm lymphocytereconstitutionafterallogeneicbloodstemcelltransplantationforhematologicmalignancies AT warkentinpi lymphocytereconstitutionafterallogeneicbloodstemcelltransplantationforhematologicmalignancies AT grosstg lymphocytereconstitutionafterallogeneicbloodstemcelltransplantationforhematologicmalignancies AT nasratik lymphocytereconstitutionafterallogeneicbloodstemcelltransplantationforhematologicmalignancies AT armitagejo lymphocytereconstitutionafterallogeneicbloodstemcelltransplantationforhematologicmalignancies AT kessingera lymphocytereconstitutionafterallogeneicbloodstemcelltransplantationforhematologicmalignancies AT bishopmr lymphocytereconstitutionafterallogeneicbloodstemcelltransplantationforhematologicmalignancies |